This article examines a 2025 preclinical study showing that hexaraphane (6-MSITC) from Japanese wasabi may activate Nrf2 through two pathways: Keap1 inhibition and direct Gsk-3β inhibition. It also discusses differences from sulforaphane and implications for chronic disease research.

A 2024 review organized research on hexaraphane/6-MSITC from Japanese wasabi across cancer, neurodegenerative disease, and obesity. It highlights effects on Nrf2 and other signaling pathways while emphasizing that most evidence remains preclinical and human trials are limited.

Nrf2 is a transcription factor that coordinates antioxidant, detoxification, and anti-inflammatory gene expression in response to oxidative stress. Its activity declines with aging, while diet, exercise, and sleep may help maintain Nrf2 responsiveness.

A 12-week open-label trial gave 9.6 mg/day of hexaraphane/6-MSITC to 15 people with ME/CFS and reported significant pre-post changes in cognitive function, brain fog, headache frequency, pain, vitality, and performance status.

“What was that person’s name again?” Many people find themselves asking this question more often after their 60s.Age-related memory decline...

Japan has entered an era of population super-aging. According to estimates from the Ministry of Health, Labour and Welfare, approximately...

NOMON & Co. is committed to creating a society in which “productive aging” is the norm. Rather than focusing solely...